{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow-up for patients last known to be alive is censored at the date of last contact. Stratified Cox regression models will be used to compare OS of the combination arm selected in the Phase II portion of the trial to OS of the single-agent azacitidine arm.","groups":[{"description":"Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nLenalidomide: Given PO","id":"OG000","title":"Arm 1: Azacitidine/Lenalidomide"},{"description":"Patients receive azacitidine as in Arm 1. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV","id":"OG001","title":"Arm 2: Azacitidine"},{"description":"Patients receive azacitidine as in Arm 1 and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nVorinostat: Given PO","id":"OG002","title":"Arm 3: Azacitidine/Vorinostat"}],"populationDescription":"This trial did not proceed to the Phase III portion. Therefore, no patients were analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival (Phase III)","type":"PRIMARY"}